Biostatistics Advance Access originally published online on November 10, 2005
Biostatistics 2006 7(2):252-267; doi:10.1093/biostatistics/kxj005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
One- and two-sample nonparametric inference procedures in the presence of a mixture of independent and dependent censoring
Department of Biostatistics, Harvard University, 677 Huntington Avenue, Boston, MA 02115, USA
Department of Preventive Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611, USA
Department of Biostatistics, Harvard University, 677 Huntington Avenue, Boston, MA 02115, USA wei{at}sdac.harvard.edu
* To whom correspondence should be addressed.
In survival analysis, the event time T is often subject to dependent censorship. Without assuming a parametric model between the failure and censoring times, the parameter
of interest, for example, the survival function of T, is generally not identifiable. On the other hand, the collection
of all attainable values for
may be well defined. In this article, we present nonparametric inference procedures for
in the presence of a mixture of dependent and independent censoring variables. By varying the criteria of classifying censoring to the dependent or independent category, our proposals can be quite useful for the so-called sensitivity analysis of censored failure times. The case that the failure time is subject to possibly dependent interval censorship is also discussed in this article. The new proposals are illustrated with data from two clinical studies on HIV-related diseases.
Keywords: Competing risks; Martingale; Sensitivity analysis; Simultaneous confidence interval; Survival analysis
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Zhang and D. F. Heitjan Impact of nonignorable coarsening on Bayesian inference Biostat., October 1, 2007; 8(4): 722 - 743. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Lagakos Time-to-Event Analyses for Long-Term Treatments -- The APPROVe Trial N. Engl. J. Med., July 13, 2006; 355(2): 113 - 117. [Full Text] [PDF] |
||||

